<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00491907</url>
  </required_header>
  <id_info>
    <org_study_id>FolicAcid881</org_study_id>
    <nct_id>NCT00491907</nct_id>
  </id_info>
  <brief_title>Effect of Folic Acid on Endothelial and Baroreceptor Function in Patients With Heart Failure</brief_title>
  <official_title>Effect of Folic Acid on Endothelial and Baroreceptor Function in Patients With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The randomized, double-blind, placebo-controlled study aim to evaluate the effect of 1-month&#xD;
      therapy with folic acid (5 mg/day) on endothelial function and baroreceptor function in&#xD;
      patients with heart failure.&#xD;
&#xD;
      Endothelial function will be studied non-invasively with flow-mediated dilation while for&#xD;
      eveluating baroreceptor function sympathetic nervous system activity will be measured&#xD;
      directly with microneurography in baseline condition and during infusion of&#xD;
      sodium-nitroprusside.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endothelial and baroreceptor function are impaired in patients with heart failure.&#xD;
&#xD;
      Impaired baroreflex control of the heart and peripheral circulation and endothelial&#xD;
      dysfunction are thought to play an important pathophysiological role in chronic heart failure&#xD;
      and confers a poor prognosis.&#xD;
&#xD;
      In patients with essential hypertension we demonstrated an improvement in baroreceptor&#xD;
      function after treatment with folic acid.&#xD;
&#xD;
      Therefore, the aim of the present randomized, double-blind, placebo-controlled study was to&#xD;
      evaluate endothelial function and baroreceptor function in patients with heart failure before&#xD;
      and after 1-month therapy with folic acid (5 mg) or placebo.&#xD;
&#xD;
      Endothelial function will be assessed with novel high-resolution ultrasound devices, which&#xD;
      allows to investigate endothelial function in vivo. This method makes use of the property of&#xD;
      the endothelium to release nitric oxide in response to shear stress and increased flow as&#xD;
      previously described. Endothelium-dependent flow-mediated dilation (FMD) and&#xD;
      endothelium-independent glycerol trinitrate (GTN) (0.4 mg sublingual, Nitrolingual Spray,&#xD;
      Pohl-Boskamp, Germany)-induced vasodilation of the brachial artery will be assessed by a&#xD;
      high-resolution ultrasound vessel wall tracking device with a 10 MHz linear array transducer&#xD;
      . FMD of the brachial artery is induced by release of a wrist cuff inflated 50 mmHg above&#xD;
      systolic pressure for 5 minutes. After sublingual GTN application, used as&#xD;
      endothelium-independent stimulus, the diameter will be recorded every 30 seconds for 6&#xD;
      minutes.&#xD;
&#xD;
      Multifiber recordings of muscle sympathetic nerve activity will be obtained from the peroneal&#xD;
      nerve posterior to the fibular head with tungsten microelectrodes. The sympathetic nervous&#xD;
      activity will be measured continuously together with ECG, respiration rate and blood&#xD;
      pressure. Baroreceptor modulation of muscle sympathetic nerve activity and heart rate would&#xD;
      be assessed by intravenous infusion of sodium nitroprusside.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    recruitment is finished&#xD;
  </why_stopped>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in endothelial function</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>change in baroreceptor function</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <condition>Heart Failure</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>folic acid 5mg/day</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Heart failure (min. NYHA ll, LVEF &lt;50%)&#xD;
&#xD;
          -  Not smokers&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unstable heart failure&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Unstabile Angina Pectoris&#xD;
&#xD;
          -  Endocrinologic disease such as Diabetes mellitus, Hypo- und Hyperthyroidism&#xD;
&#xD;
          -  Alcohol abuse&#xD;
&#xD;
          -  Epilepsia&#xD;
&#xD;
          -  Treatment with folic acid antaponists Trimethoprim, Pyrimethamin, Methotrexat..&#xD;
&#xD;
          -  Participation to one other clinical Study within 1 Month&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georg Noll, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Center, University Hospital Zurich, Zurich, Switzerland</affiliation>
  </overall_official>
  <verification_date>October 2007</verification_date>
  <study_first_submitted>June 25, 2007</study_first_submitted>
  <study_first_submitted_qc>June 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2007</study_first_posted>
  <last_update_submitted>October 1, 2007</last_update_submitted>
  <last_update_submitted_qc>October 1, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2007</last_update_posted>
  <keyword>folic acid</keyword>
  <keyword>endothelial function</keyword>
  <keyword>baroreceptor function</keyword>
  <keyword>heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

